# 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants

> **NCT04382326** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 1997 (actual)

## Conditions studied

- Pneumococcal Disease

## Interventions

- **BIOLOGICAL:** 20-valent pneumococcal conjugate vaccine
- **BIOLOGICAL:** 13-valent pneumococcal conjugate vaccine

## Key facts

- **NCT ID:** NCT04382326
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-20
- **Primary completion:** 2022-09-02
- **Final completion:** 2022-09-02
- **Target enrollment:** 1997 (ACTUAL)
- **Last updated:** 2023-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04382326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04382326, "20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04382326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*